Novartis buys Kate Therapeutics in $1.1B deal, eyes more bolt-on M&Anews2024-11-21T11:10:58+00:00November 21st, 2024|Endpoints News|
Amgen names geneticist and biotech founder to CSO postnews2024-11-21T03:39:23+00:00November 21st, 2024|Endpoints News|
Kyowa Kirin buys into Kura leukemia treatment rights for $330M+news2024-11-21T03:32:11+00:00November 21st, 2024|Endpoints News|
NewAmsterdam aces Phase 3 trial, but investors are skepticalnews2024-11-20T21:18:34+00:00November 20th, 2024|Endpoints News|
Venrock adds $500M to healthcare investing strategy after outlining 10th fund in Januarynews2024-11-20T21:09:32+00:00November 20th, 2024|Endpoints News|
FDA updates label of 33-year-old cancer drug with new dose and warningnews2024-11-20T20:54:38+00:00November 20th, 2024|Endpoints News|
When generative AI meets the FDA: First digital health adcomm kicks off discussionnews2024-11-20T18:52:15+00:00November 20th, 2024|Endpoints News|
Novo and Viking present new MASH data, but analysts remain confident in Madrigal’s Rezdiffranews2024-11-20T16:31:55+00:00November 20th, 2024|Endpoints News|
23andMe inks new research partnership as it winds down internal drug development effortsnews2024-11-20T15:29:08+00:00November 20th, 2024|Endpoints News|
Updated: Sage reports Phase 2 failure in Huntington’s disease, ends drug’s developmentnews2024-11-20T12:31:28+00:00November 20th, 2024|Endpoints News|
